Permeon goes public with protein tech

Thu, 07/28/2011 - 10:53am
Mass High Tech: The Journal of New England Technology

Biotech startup Permeon Biologics Inc. officially launched out of stealth mode today with a slew of press releases and a paper published online describing its discovery of a class of proteins that will allow protein-based therapies otherwise too complex to finally get inside a cell wall.

Founded by Harvard University professor and Howard Hughes Medical Institute investigator David R. Liu, Permeon was launched out of Flagship VentureLabs, an arm of Flagship Ventures of Cambridge. Liu is also the founder of Ensemble Therapeutics Inc., which earlier this month won a pair of U.S. Patent and Trademark Office patents it licensed exclusively from Harvard University, bringing to 53 the total number of issued or allowed patents the Cambridge biotech has worldwide.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.